| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RP9 |
| Uniprot No | Q8TA86 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-155aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMSSRPGR EDVGAAGARR PREPPEQELQ RRREQKRRRH DAQQLQQLKH LESFYEKPPP GLIKEDETKP EDCIPDVPGN EHAREFLAHA PTKGLWMPLG KEVKVMQCWR CKRYGHRTGD KECPFFIKGN QKLEQFRVAH EDPMYDIIRD NKRHEKDV |
| 预测分子量 | 21 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RP9重组蛋白的模拟参考文献示例(内容为虚构，仅作格式参考)：
1. **文献名称**: "Functional characterization of recombinant RP9 protein in retinal degeneration models"
**作者**: Smith A, et al.
**摘要**: 研究利用大肠杆菌表达系统成功制备重组RP9蛋白，证实其在体外可修复视网膜细胞中异常剪接的mRNA，减缓光感受器细胞凋亡，为基因治疗提供潜在靶点。
2. **文献名称**: "Structural insights into RP9 protein interactions with spliceosomal components"
**作者**: Chen L, et al.
**摘要**: 通过X射线晶体学解析RP9重组蛋白结构，揭示其与U5 snRNP复合物的结合域，阐明RP9在pre-mRNA剪接中的分子机制及与视网膜色素变性发病的关联。
3. **文献名称**: "RP9 gene therapy rescues photoreceptor function in a murine model"
**作者**: Gonzalez R, et al.
**摘要**: 利用腺相关病毒载体递送重组RP9蛋白至RP9突变小鼠视网膜，显著改善ERG反应及光感受器存活率，验证该蛋白的体内治疗潜力。
4. **文献名称**: "Proteomic analysis of RP9-associated pathways in retinal development"
**作者**: Wang Y, et al.
**摘要**: 通过免疫共沉淀联合质谱技术，发现重组RP9蛋白与CRX、NRL等视网膜发育调控因子存在相互作用，提示其在光感受器分化中的多重调控功能。
(注：以上文献为模拟生成，实际研究需通过学术数据库检索确认)
**Background of RP9 Recombinant Protein**
The RP9 recombinant protein is a genetically engineered variant of the human RP9 protein, encoded by the *RP9* gene (also known as *PAP1* or *DHDDS*), which plays a critical role in cellular processes such as RNA splicing and protein prenylation. Mutations in the *RP9* gene are linked to autosomal dominant retinitis pigmentosa (adRP), a degenerative eye disorder causing progressive vision loss due to photoreceptor cell death. The native RP9 protein interacts with other splicing factors and enzymes involved in post-translational modification, influencing cellular homeostasis and retinal function.
Recombinant RP9 is produced using expression systems like *E. coli* or mammalian cell cultures, enabling large-scale purification for research and therapeutic applications. Its production often includes fusion tags (e.g., His-tag) to facilitate isolation via affinity chromatography. Studies using recombinant RP9 aim to elucidate its molecular mechanisms in retinal health, particularly its role in maintaining spliceosome integrity and modulating pathways like the mevalonate pathway, which governs protein prenylation.
In therapeutic contexts, recombinant RP9 holds promise for gene therapy or protein replacement strategies to address RP9 deficiency in retinal cells. Preclinical models have explored its potential to rescue cellular dysfunction, though challenges remain in delivery efficiency and long-term stability. Additionally, it serves as a tool for screening drug candidates targeting splicing-related diseases. Research continues to optimize its structural fidelity and functional activity, bridging gaps between biochemical insights and clinical applications for inherited retinal disorders.
×
